木瓜直播

Benefits seen in patients with and without a genetic diagnosis

Trial paints a fuller picture of risk-benefit in complex patient population

Afib, hypertension, and others get updates with simplifications

More conclusive evidence for benefits on Afib burden, QoL

First adequately powered randomized trial suggests larger vessel disease isn't the right fit

Bleeding reduced -- without risk of ischemic events -- versus dual antithrombotic in Korean trial

Randomized trial shows benefits beyond heart failure with low ejection fraction, but not survival

NOTION-3 trial informs care for those with severe AS and stable CAD

RESHAPE-HF2 has provocative implications for a wider pool of TEER candidates

Randomized trial "highly encouraging" for making patients feel and function better

First randomized trial debunks common practice of tight control

Either choice is "acceptable" based on randomized study

And two aren't in the standard cardiovascular risk prediction tool

RNA silencer impresses with results in transthyretin amyloidosis cardiomyopathy